Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AMAG Pharma Submits SNDA To FDA For Ferahame Inj.

RELATED NEWS
Trade AMAG now with 

AMAG Pharmaceuticals, Inc. (AMAG: Quote) Monday said it has submitted a supplemental new drug application, or sNDA, to the Food and Drug Administration, for Feraheme Injection.

The sNDA proposes expansion of indications for the Ferahame, or ferumoxytol, injection for a treatment of iron deficiency anemia in adult patients with IDA who have failed or could not tolerate oral iron treatment.

The sNDA submission includes data from a global phase III program that evaluated the use of ferumoxytol in a broad range of adult IDA patients, all of whom had failed or could not tolerate oral iron treatment. More than 1,400 patients were enrolled in the two phase III clinical trials.

The regulatory approval of Feraheme for a broader IDA patient population would expand the company's market opportunity in the existing U.S. IV iron market, beyond its current CKD indication.

Click here to receive FREE breaking news email alerts for AMAG Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Google and Microsoft are opposing a petition by hoteliers such as Marriott International the right to block personal Wi-Fi on their premises. Elon Musk, the CEO of electric car maker Tesla Motors Inc (TSLA), on Christmas announced an upcoming upgrade for Tesla Roadster that will improve its mile-range to about 400 miles. "Roadster upgrade will enable non-stop travel from LS to SF -- almost 400 mile range. Details tmrw. Merry Christmas!,"... United Parcel Service Inc. (UPS) said Friday that it expects consumers will ship more than 800,000 packages back to retailers and merchants on January 6, 2015, or the UPS National Returns Day. By the end of the first full week in January, the package delivery giant expects to transport 4 million return...
comments powered by Disqus